Two major mechanisms have been causally implicated in the establishment of cellular senescence: the activation of the DNA damage response (DDR) pathway and the formation of senescence-associated heterochromatic foci (SAHF). Here we show that in human fibroblasts resistant to premature p16
. Cellular senescence is induced by telomere shortening or dysfunction 4, 5, 6 , DNA-damaging agents 7 or oncogene activation 8 . Oncogene-induced senescence (OIS) acts as a tumour suppressor mechanism in premalignant lesions [9] [10] [11] [12] [13] [14] [15] [16] . DDR activation is thought to enforce cellular senescence by imposing a permanent checkpoint 4, [17] [18] [19] . During cellular senescence, global induction of heterochromatin results in SAHF structures [20] [21] [22] the formation of which depends on ASF1 (anti-silencing function 1) and HIRA (histone cell cycle regulation defective homologue A) 23, 24 , and p16 INK4a (refs 20,25) . SAHF are highly condensed and heterochromatic chromosomes that are proposed to enforce cellular senescence by suppressing the transcription of genes involved in proliferation 20, 26, 27 . Although DDR and SAHF have both been causally implicated in the establishment of cellular senescence, their relationship remains undefined. Therefore, we investigated their potential interplay in senescence and cancer.
ReSulTS SAHF are preferentially associated with oncogene-induced DNA replication stress First, we tested whether DDR and global induction of heterochromatin in the form of SAHF are universal features of the senescent state induced by different genotoxic stimuli. We used human skin fibroblasts (BJ cells) that are genetically stable and resistant to culture stress and premature p16
INK4a induction 28, 29 . We analysed BJ cells that had become senescent following H-RasV12 expression (OIS), telomere shortening, exposure to ionizing radiation and treatment with H 2 O 2 or hydroxyurea. All of these stimuli induced senescence to the same extent, as demonstrated by comparable low BrdU (5-bromo-2-deoxyuridine) incorporation rates, high senescence-associated-β-galactosidase (SA-β-Gal) activity and widespread and sustained DDR ( Supplementary Fig. S1a-c ). In contrast, when cells were stained with DAPI (4,6-diamidino-2-phenylindole) and with antibodies specific for known heterochromatic SAHF components, such as the trimethylated form of Lys 9 on histone H3 (H3K9me3), heterochromatin protein 1 (HP1γ) and high mobility group A2 (HMGA2) 20, 25 , OIS cells clearly had SAHF, whereas other senescent cells showed a diffuse nuclear pattern, similar to that observed in proliferating cells (Fig. 1a) . Consistently, p16 INK4a , previously implicated in SAHF formation 20, 25 , was induced in OIS cells only ( Supplementary  Fig. S1d ). Immunoblotting analyses confirmed that H3K9me3 and HP1γ protein levels are both increased only in OIS cells (Fig. 1b) , with the sole exception of H3K9me3, which increases following hydroxyurea treatment, in the absence of detectable SAHF formation and HP1γ induction. Similar observations were made when testing a different human fibroblast cell line derived from fetal lung tissue (MRC5, Supplementary  Fig. S1e-g ). Additionally, senescence induced by repeated and prolonged exposure to ionizing radiation or etoposide (a topoisomerase inhibitor) did not result in SAHF formation (Fig. 1c, Supplementary Fig. S1h, i) . Therefore, cellular senescence can be established in the absence of overt induction of heterochromatin and SAHF formation which, in cell lines resistant to unscheduled p16
INK4a induction, are formed preferentially on oncogene expression.
Oncogene activation alters DNA replication leading to DDR activation and senescence establishment 14, 18 . Thus, we tested whether SAHF formation in OIS requires DNA replication by expressing H-RasV12 in human fibroblasts which were either proliferating or rendered quiescent by contact inhibition. Despite comparable levels of Ras expression ( Supplementary Fig. S2a ), SAHF form in proliferating cells, but do not form in quiescent cells (Fig. 2a) . Similarly, cells arrested in G1 by aphidicolin treatment (a DNA replication inhibitor) do not form SAHF on Ras expression ( Supplementary Fig. S2b) .
A key factor involved in the response to DNA replication stress is ATR 30 . To test the role of ATR in SAHF formation, we expressed oncogenic Ras in ATR-depleted cells. We discovered that stable and transient ATR knockdown by RNA interference (Fig. 2b, c) does not induce SAHF formation following Ras expression as detected by a lack of heterochromatic foci, assessed by DAPI staining and immunofluorescence microscopy performed with antibodies against H3K9me3 and HMGA2 (Fig. 2d, e) , and a lack of H3K9me3 accumulation, as assessed by immunoblotting (Fig. 2f) . Therefore, oncogene-induced SAHF formation is DNA-replication dependent and is controlled 6.9 ± 0.8 0 .9 ± 0.5 5 .6 ± 1.7
6.9 ± 2.7 2 .2 ± 0.1 7 .8 ± 2
2.7 ± 1.1 0.6 ± 0.6 7 .3 ± 1.6 by ATR, suggesting it is among the outcomes of oncogene-induced DNA replication stress.
Proliferating oncogene-expressing cells display heterochromatin induction and express e2F-target genes Inactivation of key DDR genes ATM and p53 allows oncogene-expressing cells to avoid cellular senescence 14, 18, 31 . The impact of their inactivation on heterochromatin and SAHF formation is unclear. We analysed the levels of heterochromatic markers in oncogene-expressing cells following the suppression of either ATM or p53. Surprisingly, we found that the induction of heterochromatic markers is retained in proliferating Ras-expressing cells to an extent similar to OIS cells (Fig. 3a) , suggesting that increased heterochromatin formation induced by oncogenic stimuli is independent of the proliferative or senescent state of the cells. Furthermore, single-cell analysis by confocal microscopy imaging of DAPI and heterochromatin staining in DDR-deficient oncogeneexpressing cells revealed the widespread presence of nuclear heterochromatic structures morphologically resembling SAHF, as quantified by the use of three independent markers and by the extent of nuclear staining dishomogeneity ( Fig. 3b and Supplementary Fig. S2c-e) . Notably, efficient DNA replication, as indicated by BrdU incorporation and expression of DNA replication factors (minichromosome maintenance 6, MCM6), can be detected in DDR-deficient oncogeneexpressing cells retaining heterochromatin induction (Fig. 3b, c) .
Overall, these results demonstrate that inactivation of senescenceenforcing DDR genes, such as ATM and p53, allows the proliferation of oncogene-expressing cells bearing increased levels of heterochromatin markers, and indicate that heterochromatin induction may be a general indicator of oncogene activation.
SAHF formation in OIS cells has been proposed to promote the stable repression of E2F-target genes that drive cell proliferation 20 . To investigate whether the oncogene-induced increase in heterochromatin, observed in proliferating ATM-or p53-inactivated cells, is associated with transcriptional repression of proliferative genes, we analysed the mRNA expression levels of E2F-target genes, such as minichromosome maintenance complex 6 (MCM6), proliferating cell nuclear antigen (PCNA) and cyclin A2 (CCNA2), by real-time quantitative PCR (qPCR). As expected, OIS leads to transcriptional repression of these E2F-target genes (Fig. 4a) . However, consistent with the observed cell proliferation, these same genes are not repressed in ATM-or p53-inactivated oncogene-expressing cells. MCM6 protein detection in individual cells confirms the mRNA data (Fig. 3c) . Furthermore, we performed chromatin immunoprecipitation (ChIP) with antibodies against H3K9me3 to test for the presence of this repressive chromatin mark at the promoters of E2F-target genes and understand the mechanisms regulating the expression of these genes. Consistent with previous reports 20 , H3K9me3 accumulates at transcriptionally repressed E2F-target gene promoters in OIS cells; however it is lost on inactivation of either ATM or p53 (Fig. 4b) . Therefore, inactivation of key DDR genes prevents OIS establishment and the accumulation of heterochromatic marks at specific E2F-target genes, which allows their expression without detectably impacting on the global heterochromatin increase induced by activated oncogenes.
Oncogene-expressing transformed cells and human tumours display heterochromatin induction
The maintenance of global heterochromatin induction in proliferating oncogene-expressing cells prompted us to investigate heterochromatin levels in transformed cells and human cancer specimens. We observed that transformed human fibroblasts expressing oncogenic Ras, hTERT and the SV40 early region (ELR) 32 display high levels of heterochromatin markers organized in nuclear structures ( Supplementary Fig. S2f-h ). Consistent with our observations in ATM or p53 knocked-down cells expressing oncogenic Ras, these transformed cells also expressed E2F-target genes and had reduced levels of H3K9me3 at their promoters ( Supplementary Fig. S2i, l) . To determine whether heterochromatin induction is associated in vivo with oncogenic events, we analysed two types of tissues: a normal respiratory epithelium that had probably undergone X-ray-induced cellular senescence (as suggested by persistent γH2AX staining one year after treatment; Supplementary Fig. S3a ) and, as a model of oncogene-induced stress, untreated head and neck squamous cell carcinomas (HNSCC). Although we found detectable heterochromatin induction organized in structures resembling SAHF in HNSCC samples, we failed to detect similar structures in the irradiated normal tissue (Supplementary Fig. S3b ). Together, these results indicate that global heterochromatin induction is associated with oncogenic events, retained in human transformed cells and is present in vivo in tumoral specimens.
We next examined heterochromatin levels in lung, colon, and head and neck cancer samples, and compared them to their normal counterparts. We observed significantly increased H3K9me3 expression in tumours, compared with normal tissues (Fig. 5a, b) . Similarly, studies in the Oncomine database 33 indicate a consistent upregulation of HP1γ, HP1β, HMGA1 and HMGA2 in several tumour types (Fig. 5c ). Neither H3K9me3 nor HP1γ correlate with a decrease in Ki67 expression, a marker of proliferation, in any of the three tumour types we analysed (Fig. 5d) . Indeed, single-cell analysis of HNSCC revealed Ki67 expression in H3K9me3-or HP1γ-positive cells (Fig. 5e, Supplementary Fig. S3c ), suggesting that also in tumour samples heterochromatin induction does not affect the expression of proliferative genes.
In agreement with our observations that heterochromatin formation is dependent on oncogene-driven DNA-replication stress, along with the reported induction of CDC6 by oncogenes and the ability of CDC6 to induce DNA replication stress in vitro 14 , we found that heterochromatin formation in colon and lung cancers positively correlates with CDC6 expression levels ( Supplementary Fig. S3d ).
Based on studies in the haematopoietic system 12 , heterochromatin formation has been proposed to be a tumour-suppressive mechanism. According to this model, heterochromatic markers would be expected to be downregulated or lost during cancer progression. Instead, H3K9me3 staining is not reduced with increasing tumour stage in lung or colon cancer (Fig. 5f ), whereas p53 inactivation is observed in the same tumours (Fig. 5g) . In addition, heterochromatic markers inversely correlate with γH2AX levels in HNSCC and colon cancer samples ( Supplementary Fig. S3e, f) . Overall, these data indicate that induction of heterochromatin is compatible with cell proliferation in human tumours and is maintained, or even increased, during tumour progression.
Oncogene-induced heterochromatin restrains DDR signalling
We wanted to understand the molecular mechanisms responsible for the maintenance of elevated levels of heterochromatin during tumour progression. Previous reports suggested that heterochromatin poses a barrier to DDR signalling [34] [35] [36] [37] [38] [39] . We reasoned that global heterochromatin formation induced by oncogene activation may modulate DDR signalling.
Therefore, we investigated the relationship between heterochromatin structures triggered by oncogene activation and DDR foci in the nuclear space of oncogene-expressing cells. In OIS cells, we observed that γH2AX foci and SAHF coexist in the same cell but do not colocalize (Fig. 6a) . γH2AX foci are preferentially proximal to, but excluded from, SAHF. The observed lack of γH2AX staining in SAHF is not due to impaired antibody accessibility, as histone H2AX is readily detectable in heterochromatin regions. Line traces drawn through OIS cells revealed a sharp inverse correlation between γH2AX signal intensity and heterochromatic domains, suggesting that SAHF exclude γH2AX foci. Similarly, we observed that the DNA damage sensors RAD50 and NBS1, components of the MRE11-RAD50-NBS1 complex, and the activated form of ATM (ATM phosphorylated at Ser 1981) are also excluded from SAHF ( Fig. 6b-d) .
Thus, we hypothesized that by hindering access of DNA-damage sensors and associated DDR factors, oncogene-induced heterochromatin can restrain DDR signalling in oncogene-expressing cells. To test this hypothesis, we studied the effects of heterochromatin perturbation in OIS and Ras-transformed ELR cells. We treated OIS, ELR and control fibroblasts with a small-molecule inhibitor of SUV39 methyltransferase (SUVi), the key enzyme involved in H3K9 methylation 40, 41 . As expected, SUVi reduces H3K9 trimethylation and perturbs heterochromatin structures ( Fig. 7a, d ). We observed a significant increase in intensity of γH2AX foci ( Suppression of either SUV39h1 or HP1γ preferentially increases DDR signalling in oncogene-expressing cells ( Supplementary Fig. S5a-e) . Therefore, we conclude that heterochromatin perturbation leads to an increase of DDR signalling in oncogene-expressing cells. As heterochromatin induction is specifically associated with oncogenic events and is not lost during cancer progression, we reasoned that it could represent an attractive target for cancer therapy in that, by boosting DDR signalling pathways, heterochromatin perturbation may cause apoptosis of tumour cells.
At present, SUVi have not been developed for clinical use; however, another class of chromatin-modifying agents, histone deacetylase inhibitors (HDACi), are currently considered promising anticancer drugs 43 , although their mechanisms of action are still unclear 44 . In addition, HDAC1 is known to drive the assembly of heterochromatin complexes and heterochromatin induction during cellular senescence 45 . We therefore tested the effects of the HDACi valproic acid (VPA) on heterochromatin in oncogene-expressing fibroblasts. VPA treatment increased γH2AX signalling in oncogene-expressing cells, but not in control cells, in association with increased histone acetylation, oncogene-induced heterochromatin perturbation and loss of exclusion of DDR factors from SAHF ( Supplementary Fig. S5f-i and S4c, e, g).
We then tested the effects of VPA on an in vitro model relevant for cancer studies: mammary epithelial cells (MCF10a) expressing oncogenic Ras or infected with a control empty vector. As expected, oncogenic Ras induced focal accumulation of increased H3K9me3 levels as detected by immunostaining (Supplementary Fig. S6a ). Also in this system, VPA treatment increases γH2AX signalling in proliferating oncogeneexpressing cells, but not in normal epithelial cells (Fig. 8a, c) . Strikingly, increased DDR signalling leads to the activation of the apoptotic programme and specific elimination of oncogene-expressing cells, sparing cells that do not express an oncogene (Fig. 8b, c) .
We next tested the impact of heterochromatin perturbation in the human colon cancer cell line HCT116 carrying an activating mutation in the K-Ras gene. These cancer cells display dense nuclear heterochromatic signals, as detected by microscopy using DAPI and H3K9me3 staining, and accumulate heterochromatin markers to an extent similar to oncogenic RAS-expressing cells ( Supplementary Fig. S6b, c) . On treatment in vitro with HDACi and either VPA or panobinostat (a HDACi currently in phase II clinical trials 46 ), HCT116 cells show perturbation of oncogeneinduced heterochromatic structures ( Supplementary Fig. S6d ), increased DDR signalling and subsequent induction of apoptosis ( Supplementary  Fig. S7a-g ). Importantly, HDACi treatment does not induce DNA damage per se as tested by TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labelling) and comet assays ( Supplementary Fig. S7h , i) and does not affect gene expression of key DDR components H2AX and ATM ( Supplementary Fig. S7l ). We next used this human cancer cell line as a xenograft model and implanted untreated HCT116 cells subcutaneously in immunodeficient mice and allowed tumours to form. Mice were then treated with panobinostat or vehicle. Whereas the tumour mass grew exponentially in vehicle-treated mice, HDACi treatment led to a dramatic reduction of tumour growth (Fig. 8d) . Analysis of the residual tumour revealed that HDACi treatment increased histone acetylation, γH2AX accumulation and apoptosis (Fig. 8e, f and Supplementary Fig. S8a ). Therefore, HDACi treatment, by increasing DDR signalling and apoptosis, induces in vivo regression of the tumoral mass. Importantly, this treatment had no obvious detrimental effects on mice, as assessed by measurement of body weight and grooming (data not shown).
Finally, we tested the dependency on DDR genes on the observed HDACi-induced apoptosis. H2AX or ATM knocked-down HCT116 cells and controls were exposed to HDACi. DDR-inactivated cells displayed a reduced induction of apoptosis, as detected by both TUNEL assay and single-cell detection of the activated form of caspase 3 (Fig. 8g, h and Supplementary Fig. Sb-g ). This is consistent with a previous study 47 . ATM kinase activity is required, as a specific ATM kinase activity inhibitor causes a decrease in apoptosis in HCT116 cells treated with HDACi ( Fig. 8i and Supplementary Fig. S8h-l) . 
DISCuSSION
In summary, our results show that global heterochromatin induction is a general hallmark of oncogene-induced stress that is retained following DDR inactivation, transformation and throughout human cancer progression. Heterochromatin perturbation in oncogene-expressing cells enhances DDR signalling culminating in cell death by apoptosis (see model in Fig. 8l) .
The initiating event that leads to SAHF formation and global induction of heterochromatin is presently unclear. p16
INK4a has been shown to have a causative role in SAHF formation 20, 25 . Although p16 INK4a is consistently induced in OIS, culture stress contributes to its accumulation in some human fibroblast strains undergoing replicative senescence 28 . In strains resistant to this kind of stress, senescence triggered by telomere shortening is associated with low p16
INK4a levels and strongly impaired SAHF formation, as we and others have observed 20 . These in vitro observations are consistent with the reported absence of SAHF formation in fibroblasts obtained from the skin of aged primates that display persistent DNA damage accumulation at telomeres 48 (U. Herbig, personal communication). These observations are also consistent with the altered chromatin status, including reduced expression of heterochromatic markers, in human fibroblasts from normally aged individuals and from Hutchinson-Gilford progeria syndrome (HGPS) patients 49 . The induction of SAHF following the sole expression of CDC6-a positive DNA-replication regulator induced by several oncogenes 18 -in vitro 14 and, as reported here, the correlation between heterochromatin markers and CDC6 levels in human tumours and DNA replication-dependent formation of SAHF in a manner controlled by ATR, all seem to suggest a . Moreover, activation of ATR in the absence of DNA damage has been proposed to be sufficient for SAHF formation 54 . Consistent with the notion that transformed and ATM-or p53-inactivated oncogene-expressing cells are continuously exposed to DNA replication stress 18, 14, 31 , we detected heterochromatin induction in these proliferating oncogene-expressing cells. These results also show that global heterochromatin induction is compatible with the transcription of proliferative genes and suggest the involvement of DDR pathways in the control of heterochromatic repressive marks on their promoters. This is in agreement with the recently demonstrated role of ATM in the modulation of the growth-suppressive functions of E2F1 in osteosarcomas 55 . Oncogene-induced heterochromatin has been proposed to restrain cell proliferation 20 and indeed SUV39h1 has tumour-suppressive functions in mice 12 . However, the same authors point out that this may be limited to the haematopoietic system 12, 20 . SUV39h1 has also been reported to be upregulated in colon cancer 56 and, in agreement with several studies reported in Oncomine database 33 , we and others 57 have observed increased expression of heterochromatic markers in proliferating tumour samples. These findings, consistent with the lack of reported widespread inactivating mutations of genes encoding heterochromatin factors during cancer progression, may indicate additional unexplored roles for heterochromatin induction in tumorigenesis.
Heterochromatin has been reported to pose a barrier to DDR signalling [34] [35] [36] [37] [38] [39] . In Drosophila, HP1 prevents DDR activation at chromosome ends 58 and in mammals it modulates DDR activation 59 and ASF1 inactivates DDR 60 . These results are consistent with a model in which oncogene-induced heterochromatinization has a role in restraining DDR signalling pathways. Oncogene-induced heterochromatin may both restrain the access of DNA damage sensors to DNA lesions and impair local signal amplification, thus preventing the formation of detectable DDR foci.
Our observations that heterochromatin perturbation increases DDR signalling, specifically the ATM branch, and induces apoptosis suggest that heterochromatin induction contributes to preserve cell viability in oncogene-expressing cells. Chromatin modulation may therefore be exploited therapeutically to boost the DDR caused by oncogene activation, leading to cell death. Thus, our results suggest an additional mechanism for the observed efficacy of HDACi in cancer therapy, especially in solid tumours 43, 44 , and provide elements for critical consideration of their use in combination with DDR inhibitors. Next generation HDACi are now being developed to overcome current limitations in the pharmacological properties of the approved drugs and to achieve better clinical results, also in combination with additional epigenetic interventions, as recent clinical trials with improved therapeutic effect suggest 44 . Our results indicate that treatment of oncogene-expressing cells with therapies aimed at heterochromatin alteration may benefit from the analysis of DDR activation and epigenetic status of the tumour.
MeTHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology/ 
M E T H O D S

MeTHODS
Cell Culture and treatments. Early passage BJ, MRC5, MCF10a, HCT116 (The American Type Culture Collection, ATCC) and ELR cells were grown under standard tissue-culture conditions. OIS cells were generated as described 18 . Telomere-initiated senescent BJ cells were obtained by extensive passaging of BJ cells. Ionizing radiation-induced senescent cells were obtained with a 20 Gy dose and analysed two weeks later. H 2 O 2 was used for 1 h at 500 μM concentration, hydroxyurea was used for two weeks at 600 μM concentration and cells were analysed after two weeks, etoposide was used at 170 nM every three days for two weeks. Valproic acid (VPA, SIGMA) was used at 10-50 mM concentration, as indicated, for 24 h (until 72 h for Fig. 8b ). Suv39 methyl transferase inhibitor (Chaetocin, SIGMA) was used at 0.4 nM concentration for 24 h. Panobinostat was used in vitro at 0.004-1 μΜ range concentration for 24 h on HCT116 cells. KU55933 (KuDOS Pharmaceuticals) was used at 20 μM for 24 h on HCT116 cells. Quiescent cells were obtained by contact-inhibition. Aphidicolin (Sigma) was used at 2 μg ml -1 concentration. SA-β-galactosidase assay was performed as described 18 . Plasmids. pBABE-Puro H-RasV12, pBABE-Hygro H-RasV12, pRETRO-SUPER shp53, pRETROSUPER shATM, pRRL.SIN-18 Lenti GFP and Lenti H-RasV12 and corresponding empty vectors were used as described in ref. 18 . pLKO.1 shSUV39h1, pLKO.1 shHP1γ, pLKO.1 shH2AX and pLKO.1-puro were obtained from the RNAi Consortium 61 (Broad Institute) and used to infect OIS, ELR, BJ, MCF10a and HCT116 cells. pLKO.1 ATR shRNA was obtained from O. F-Capetillo (CNIO).
siRNA. ATR siRNA used is Dharmacon SMART pools: 5ʹ-GAACAACACUGCU-G GUUUG-3ʹ, 5ʹ-GCAACUCGCCUAACAGAUA-3ʹ and 5ʹ-ACUGAUGGCUGAUUAUUUA-3ʹ. ATM siRNA is Dharmacon SMART pools: 5ʹ-GAAUGUUGCUUUCUGAAU-3ʹ, 5ʹ-UAGACAGAAUUCCCAAAUAA-3ʹ, UAUAUCAC CU GUUUGUUAG-3ʹ and 5ʹ-AGGAGGAGCUUGGGCCUUU-3ʹ. GFP siRNA was used as control: 5ʹ-AAGCU ACCUGUU CCA UG GCCA-3ʹ. shRNA sequences: SUV39h1 shRNA, 5ʹ-CCGG GCAGGTGTACAACGTCTTCATCT-CGAGATG AAGACG TTGTACACCTGCTTTTTTG-3ʹ; HP1γ shRNA,
ʹ -C C G G G C G T T T C T TA AC T C T C AG A A AC T C G AG T T T C T G -AGAGTTAAGAAACGCTTTTT-3ʹ
; p53 shRNA, 5ʹ-AGTAGATTACCACT GGAGTC TT-3ʹ; ATM shRNA, 5ʹ-CGAAAGTTGA CAGCCA AAGTCTT-3ʹ; ATR shRNA, 5ʹ-CCGGGCC AAAGTATTT CTAGCCTAT CTCGA GATAGGC-TAGAAAT ACTTTGGCTTTTTG-3ʹ; H2AX shRNA, 5ʹ-CCGG CGACAA CA AG-AAGACGC GAATC TCGAGA TTC GCGTCTTC TTGTTGTCGTTTTTG-3ʹ.
Immunofluorescence microscopy. Cells were fixed and probed as previously described 18 . To detect SAHF, DAPI was used at 0.13 μg ml -1 for 30 s at room temperature. Images were acquired using a wide field Olympus Biosystems Microscope BX71 and MetaMorph software. Confocal sections were obtained with a Leica TCS SP2 AOBS confocal laser microscope by sequential scanning. For focus intensity, images were acquired using a wide field Olympus BX61 upright microscope, the software ScanR (×40 magnification, N.A. 0.90) and analysed by ImageJ software (version 1.42), using the Object_Counter3D plugin. A threshold value was used to distinguish individual foci (from 1.5 to 4 μm diameter size); between 200 and 2000 nuclei per sample were analysed. Comparative immunofluorescence microscopy analyses were performed in parallel with identical acquisition and analysis parameters. For the distribution of signal intensity, line traces were generated among foci with the line drawn using RGB profiler ImageJ plugin. To evaluate the nuclear staining dishomogeneity the standard deviation relative to the average intensity of SAHF structures within the nuclei was used.
Immunohistochemistry (IHC) and tumour samples analyses. Formalin-fixed paraffin-embedded sections from 15 surgically removed HNSCC and 20 colon carcinomas and 42 lung carcinomas from a previously described tissue bank 62 were analysed, after local ethical committee approval. The samples were taken from patients that had not undergone any chemo-or radiotherapy before surgical resection. Immunohistochemistry was performed according to the indirect streptavidin-biotin-peroxidase method, as previously described 2 . Two independent pathologists performed the evaluation and the results were analysed using the SPSS v12.0 software. P values were calculated computing the Spearman's correlation coefficient, testing the Null Hypothesis of lack of association and One-way ANOVA as indicated.
Immunohistochemistry (IHC) of tumour xenografts. Tumour xenografts were recovered 2 h after last compound administration and fixed in formalin. Formalin-fixed and paraffin-embedded tumours were stained for haematoxylin/ eosin, γH2AX, histone H4 acetylation and caspase-3 activation by the following procedures. For γH2AX staining: formalin-fixed and paraffin-embedded xenograft tissue sections were deparaffinized, re-hydrated, unmasked in 0.25 mM EDTA at 55 °C overnight at 4 °C, and treated for 5 min with 3% H 2 O 2 . Slides were then incubated overnight at 4 °C with anti-γH2AX antibody, revealed using the EnVision Plus/HRP detection system and counterstained with haematoxylin. For histone H4 acetylation: formalin-fixed and paraffin-embedded xenograft tissue sections were deparaffinized, re-hydrated, unmasked using TEG (10mM Tris, o.5mM EGTA) buffer at pH 9 and treated for 5 min with 3% H 2 O 2 . Slides were then incubated overnight at 4 °C with anti-histone H4 acetylated antibody, revealed using the EnVision Plus/HRP detection system (Dako) and counterstained with haematoxylin. For caspase-3 activation: formalin-fixed and paraffin-embedded xenograft tissue sections were deparaffinized, re-hydrated, unmasked for 10 min in 0.25 mM EDTA at 95 °C, and treated for 5 min with 3% H 2 O 2 . Slides were then incubated for 2 h at room temperature with anti-activated caspase-3 antibody, revealed using the EnVision Plus/HRP detection system and counterstained with haematoxylin.
Xenograft model and in vivo HDACi treatment. Female 4-6 weeks old (20-25 g) CD1 nude mice were obtained from Charles River. 5 × 10 6 HCT116 colon carcinoma cell lines (ATCC) in a volume of 0.2 ml were implanted subcutaneously. Following implantation, tumours were allowed to grow to a size of 100 mm 3 before starting daily treatments. Panobinostat, produced in-house following synthesis reported in patent application WO2007/146718, was dissolved in vehicle (5% DMSO and 1% TWEEN 80 in PBS) and dosed by intravenous daily administration. Tumour growth was measured using Vernier calipers and tumour volume was calculated using the equation (l × w Immunoblotting. Cells were lysed in sample buffer and 20-50 μg of whole cell lysate were resolved by SDS-PAGE (SDS-polyacrylamide gel electrophoresis), transferred to nitrocellulose and probed as previously described 18 .
Database. Gene expression data on heterochromatin proteins HP1γ, HP1β, HMGA1 and HMGA2 were retrieved from the Oncomine, a public cancer microarray database, (www.oncomine.org).
Apoptosis assay and flow cytometry analysis. Apoptosis in vitro was quantified by FACS (fluorescence-activated cell sorting) analysis of the sub-G1 fraction after propidium iodide staining (50 μg ml -1 ) of ethanol-fixed and permeabilized cells or by TUNEL assay using In Situ Cell Death Detection Kit, Fluoresceine (Roche) on acetone/methanol fixed cells. qPCR. Total RNA was isolated from cells using RNAeasy (Qiagen) according to the manufacturer's instructions, and treated with DNAse before reverse transcription. cDNA was generated using the Superscript II Reverse Transcriptase (Invitrogen). The cDNA was used as template in real-time quantitative PCR reactions with SUV39h1 specific primers on a Roche LightCycler 480 Sequence Detection System. The reactions were prepared using SyBR Green reaction mix from Roche. Ribosomal protein P0 (RPP0) was used as a control gene for normalization. Primer sequences for qRT-PCR: RPPO-fw, 5ʹ-TTCAT TGTGGGA GCAGAC-3ʹ; RPPO-rev, 5ʹ-CAGCAGT-TTCTCC AGAGC-3ʹ; SUV 39h1-fw, 5ʹ-GTCAT GGAGTACGTGGG A GAG-3ʹ; SUV39h1-rev, 5ʹ-CCTGAC GGTCGTAGATCTGG-3ʹ; ATM-fw, 5ʹ-GCAA-CT GTAC CAAGAA GAGTCCAA-3ʹ; ATM-rev, 5ʹ-GCAG GAAAAAGCCAG-ATGCA-3ʹ; H2AX-fw, 5ʹ-TCAGCTCTCCCT CCATCTTC-3ʹ; H2AX-rev, 5ʹ-TGTGCCTGTTACCAAGTGCT-3ʹ.
TaqMan Gene Expression Assays was used to study E2F-target genes expression (Fig. 4a, Supplementary Fig. S2i ). The cDNA was used as template in real-time quantitative PCR reaction performed on an Applied Biosystems ABI Prism 7900HT Sequence Detection System. The following assays were used DOI: 10.1038/ncb2170 from Applied Biosystems: Hs00427214_g1 (PCNA); Hs00195504_m1 (MCM6); Hs00153138_m1 (CCNA2); 4319413 E (18S), Hs99999189_m1 (p16
INK4a
).
Chromatin immunoprecipitation (ChIP) analysis. ChIPs were performed essentially as described 63 . Briefly, cells were cross-linked with 1% formaldehyde in PBS for 10 min at 37 °C and quenched in 125 mM glycine in PBS for 5 min at 4 °C. The cells were collected by centrifugation and sonicated in lysis buffer (0.33% SDS, 150 mM NaCl, 10 mM EDTA, 50 mM Tris-HCl at pH 8.0 and 1 × protease inhibitor cocktail) to generate chromatin fragments of ~500 bp in length. The material was clarified by centrifugation, diluted 10-fold in ChIP buffer (0.5% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl at pH 7.9 and 1 × protease inhibitor cocktail), and pre-cleared with protein A-agarose beads. The pre-cleared, chromatin-containing supernatant was used in immunoprecipitation reactions with the primary antibodies described below. ChIP DNA was then extracted with Chelex 100 at 95 °C for 15 min and purified using DNA purification kit (Quiagen). For gene-specific ChIP analyses, quantitative real-time PCR (qPCR) was used to determine the enrichment of immunoprecipitated material relative to the input material using gene-specific primer sets to the specified regions. Immunoprecipitated DNA from 5 × 10 6 cell equivalents was resuspended in 0.5 ml of 10 mM Tris at pH 8.0. Real-time PCR was performed with 9.6 μl of DNA per reaction and 200 nM primers, diluted in a final volume of 20 μl in SYBR Green Reaction Mix (Perkin Elmer). Each ChIP experiment was performed at least three times with independent chromatin isolates to ensure reproducibility. Supplementary Fig. 9 continued. Figure S9 continued 
